{"id":"W3165577823","doi":"10.1136/annrheumdis-2021-eular.325","title":"AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adalimumab; Medicine; Internal medicine; Rheumatoid arthritis; Randomization; Immunogenicity; Biosimilar; Gastroenterology; Nuclear medicine; Randomized controlled trial; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002024671,0.000592042,0.001567664,0.0004330292,0.0003273433,0.001003001,0.0004264763,0.001014993,0.001479148],"category_scores_gemma":[0.001370079,0.0002095659,0.002493655,0.0004543044,0.0005761248,0.000978419,0.0003047879,0.001837119,0.0004092443],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006399378,"about_ca_system_score_gemma":0.000351353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001069231,"about_ca_topic_score_gemma":0.0007178023,"domain_scores_codex":[0.9992187,0.0002344893,0.00006762295,0.0001846706,0.00011988,0.0001746466],"domain_scores_gemma":[0.9988569,0.0002928108,0.0003502178,0.0001237521,0.0001132411,0.0002631353],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7723663,0.01675905,0.1024899,0.0004817314,0.004225338,0.0007565827,0.0004475479,0.002054549,0.01714106,0.0001278571,0.0007400604,0.08241002],"study_design_scores_gemma":[0.04700756,0.4620679,0.4710871,0.00007113106,0.007112367,0.0009615559,0.0003848165,0.002283925,0.006950247,0.0002174589,0.00172442,0.0001315694],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979304,0.001390291,0.00009292627,0.00003958329,0.00002337067,0.00002838557,0.0001816033,0.00001027894,0.0003030743],"genre_scores_gemma":[0.9985135,0.0003771278,0.00007304109,0.00006715635,0.00004542886,0.0000215466,0.0004654747,0.000003386733,0.0004332838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002024671,"threshold_uncertainty_score":0.01070756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03003932335974003,"score_gpt":0.2870993156697347,"score_spread":0.2570599923099947,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}